Bridgewater Associates LP reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 89.6% during the 3rd quarter, according to the company in its most recent ...

Under the deal, eligible patients – aged 12 or over who have two copies of the F508del mutation gene, or one copy of F508del and a minimal function (MF) mutation – will be able to get ...

If approved Symkevi will be used in combination with Kalydeco and be the treatment for the CFTR protein defect in CF patients who have one copy of the F508del mutation and a copy of one of 14 ...

After hours: November 29 at 4:12 PM EST Loading Chart for VRTX ...

with CF, eligible if change in FEV 1 ≥10% or sweat chloride decreased by at least 15 mEq/L at day 15 and week 8 Age ≥12 years Homozygous F508del Part 1 Ivacaftor (VX-770) 150 mg twice daily (n ...

Future Microbiol. 2013;8(8):967-978.

Cystic fibrosis (CF) is a life-shortening genetic disease affecting approximately 70 000 individuals worldwide. Until recently, drug development efforts have emphasised therapies treating downstream ...